BackInnate Pharma Overview

Innate Pharma Total Current Liabilities

Track Innate Pharma's total current liabilities ($33M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$32.84M
↑ 11.61% YoYΔ $3.42M vs prior year quarter

Peer trimmed avg / median

Loading

Innate Pharma Total Current Liabilities History

Loading

Innate Pharma vs. peers: Total Current Liabilities Comparison

Loading

Innate Pharma Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Innate Pharma (IPHA) FAQ

As of the most recent data (June 2026), IPHA shows a total current liabilities of $33M. That compares with $29M in the prior-year period — up 11.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IPHA's total current liabilities is now $33M (was $29M) — a 11.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Innate Pharma is outperforming or lagging.

Tracking IPHA's total current liabilities over time shows whether Innate Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $33M That compares with $29M in the prior-year period — up 11.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Innate Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $33M) with ownership activity and broader fundamentals.

Innate Pharma's total current liabilities is $33M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.